Trial Details
ACTIVE_NOT_RECRUITINGBasic Information
| Clinical ID | c1084 |
|---|---|
| Identifier | NCT04996797 |
| Trial Title | A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Ulcerative Colitis |
| Interventions | DRUG: Tulisokibart|DEVICE: Companion Diagnostic (CDx) Testing|OTHER: Placebo |
Participant Information
| Sponsor | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
|---|---|
| City | Mobile |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2021-07-28 |
|---|---|
| Primary Completion Date | 2023-06-06 |
| Completion Date | 2026-06-30 |